• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30

Gallery

Business Details

Creating precisely tuned medicines so patients can breathe freely

Lyra Therapeutics is a clinical-stage company developing medicines precisely designed to target ear, nose and throat (ENT) diseases.

Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients.

Building on expertise in materials science, drug development and formulation, the Lyra team has developed a proprietary platform that is designed to enable sustained, local delivery of medications over an extended period of time, directly targeting tissue deep in the nasal passages. Based on clinical results, this new therapeutic approach has the potential to provide significantly improved patient outcomes beyond the limited treatment and surgical options currently available for ENT diseases.

Headquartered in the Boston area, Lyra Therapeutics was founded by academic luminaries in the fields of chemistry, materials science and biotechnology, and is backed by leading life science investors.

Technology

Our product platform is a transmucosal therapeutic system comprised of a drug administered through a polymeric matrix, precisely designed to target ear, nose and throat (ENT) diseases. Lyra’s product candidates are designed to provide medicine directly to diseased tissues that are not accessible with conventional therapeutic approaches.

This proprietary therapeutic consists of:

  • Long-acting medication, custom formulated for consistent topical dosing over several months
  • Polymeric matrix, with flexibility to contour to the treatment area and adapt to inflamed remodeling tissue

The therapeutic is administered by a physician in the office. It can be easily removed if desired and is biodegradable.

Lyra has a robust global portfolio of intellectual property. These patents cover all aspects of the transmucosal therapeutic system, including controlled drug release and materials science for adaptive applications in biologic environments. All intellectual property protecting the Lyra platform has been developed and is owned by the company.

Type:
Manufacturing Partner, Production
Establishment year:
1995
Employees:
200

LYR-210

LYR-210 for Chronic Rhinosinusitis

Our lead product candidate, entering Phase 2, is LYR-210 for chronic rhinosinusitis (CRS).

LYR-210 uses Lyra’s transmucosal therapeutic system to deliver a custom long-acting formulation of an approved, proven steroid, mometasone furoate, deep into the sinonasal tissues that are difficult to access with conventional therapeutic approaches.

LYR-210 has been designed to be placed directly into inflamed sinonasal passages of pre-surgical patients and release topical steroid anti-inflammatory therapy for up to six months. With its innovative design, LYR-210 can be administered by a physician in a routine office visit.

In Phase 1 clinical testing, LYR-210 was shown to be safe and well-tolerated and demonstrated significant improvements in clinical outcomes in patients with CRS. LYR-210 was successfully administered to CRS patients both with and without nasal polyps.

LYR-210 has the potential to be one of the first approved drug products for CRS and is the only product in development offering six months of drug therapy with a single administration.

Map Location

Map Directions

BUSINESS REVIEWS

Add review

There are no reviews at the moment

We use cookies to ensure you get the best experience on this website Privacy Policy